Figure - available from: Frontiers in Microbiology
This content is subject to copyright.
Source publication
Background
Gut microbiome dysbiosis has been implicated in various gastrointestinal and extra-gastrointestinal diseases, but evidence on the efficacy and safety of fecal microbiota transplantation (FMT) for therapeutic indications remains unclear.
Methods
The gutMDisorder database was used to summarize the associations between gut microbiome dysbi...
Similar publications
Clear aligner treatment seems to be a good option for the periodontal patient by the reason of being removable. Multibracket appliances are more difficult to mantain clean and some bacteria might prefer to adhere on the archwire. A systematic review was carried out using 4 electronic databases (Pubmed-Medline, Scopus, Cochrane and Web of Science)....
CRPC remains a significant challenge in prostate cancer research. We aimed to elucidate the role of gut microbiota and its specific mechanisms in CRPC using a multidisciplinary approach. We analyzed 16S rRNA sequencing data from mouse fecal samples, revealing substantial differences in gut microbiota composition between CRPC and castration-sensitiv...
Chronic kidney disease (CKD) is a progressive loss of renal function in which gut dysbiosis is involved. Fecal microbiota transplantation (FMT) may be a promising alternative for restoring gut microbiota and treating CKD. This study evaluated the changes in CKD progression in patients treated with FMT. Patients with diabetes and/or hypertension wit...
Objective
Stunting is a condition of impaired growth in children resulting from chronic malnutrition, characterized by shorter stature compared to peers of the same age. This condition leads to salivary gland dysfunction, which triggers oral dysbiosis and increases the risk of periodontal disease in children. Scaling and root planing (SRP) is the g...
Introduction
Numerous studies have demonstrated that C57BL/6 mice exhibit superior growth rates and overall growth performance compared to DBA mice. To investigate whether this discrepancy in growth performance is linked to the composition of gut microorganisms, we conducted fecal microbiome transplantation (FMT) experiments.
Methods
Specifically,...
Citations
... Fecal microbial transplantation (FMT) is a promising intervention to reshape GM, offering potential treatment for metabolic dysfunction and autoimmune diseases. 128 It has been investigated in various contexts, including MetSyn, non-alcoholic fatty liver disease, and obesity in both animal and human studies. 129 Patients with reduced GM diversity have shown a significant increase in microbial diversity after receiving fecal transplants from lean and healthy donors. ...
Obesity is a chronic inflammatory disease defined by an excessive accumulation of body fat. The human gut microbiota (GM) is an intricate ecosystem of microorganisms living symbiotically within the gastrointestinal tract and has emerged as a key player in health and metabolic diseases. Recently, several studies have increasingly revolved around understanding the specific compositions and strains of GM and their potential impact on obesity. This review provides a summary of the most recent findings regarding obesity and newly developed therapies that show exceptional efficacy in treating this condition. In addition, it explores different GM strains that may contribute to the progression and development of obesity. This article summarizes the molecular insights involved in the relationship between obesity and GM, the characteristics of this ecosystem, and its involvement in human metabolism, energy balance, and inflammation leading to obesity. Furthermore, it examines the bacteria most engaged in managing obesity. These findings contribute to a better understanding of this significant and intricate relationship, ultimately aiding in obesity prevention.
... The exacerbation rate of IBD in adults is 26.8%, and 10.8% in children. 122 Effective management strategies include pre-screening for infections, close monitoring during the procedure, and the use of post-FMT antibiotics in cases of confirmed infections. Prompt recognition and intervention can help mitigate severe outcomes. ...
Colorectal cancer (CRC) remains a leading cause of cancer-related deaths worldwide, with its progression intricately linked to gut microbiota dysbiosis. Disruptions in microbial homeostasis contribute to tumor initiation, immune suppression, and inflammation, establishing the microbiota as a key therapeutic target. Fecal microbiota transplantation (FMT) has emerged as a transformative approach to restore microbial balance, enhance immune responses, and reshape the tumor microenvironment. This review explores the mechanisms underlying FMT’s therapeutic potential, evaluates its advantages over other microbiota-based interventions, and addresses challenges such as donor selection, safety concerns, and treatment standardization. Looking forward, the integration of FMT into personalized CRC therapies requires robust clinical trials and the identification of predictive biomarkers to optimize its efficacy and safety.
... Fecal microbiota transplantation (FMT), an emerging therapy for modulating the gut microbiota, has therapeutic potential for recurrent Clostridioides difficile infections (rCDIs), inflammatory bowel disease, and gastrointestinal tract tumors. [17] However, there is a lack of basic and clinical trial-based confirmation of the efficacy of FMT in HD patients. ...
... Numerous studies have consistently shown that aGvHD patients often suffer from gut microbiota dysbiosis, which primarily manifests as a decrease in microbial diversity and an altered composition of specific bacterial taxa [118,119]. This dysbiosis can be attributed to various factors, including the use of broad-spectrum antibiotics, conditioning regimens, and damage to the intestinal epithelium throughout heavy treatment protocols such as therapeutic cycles, and rounds of chemotherapies leading to the transplantation process [120]. Moreover, the complex interplay between antibiotics, the gut microbiome, and GvHD presents a paradox, as antibiotics are often necessary for infection prevention but can also contribute to promoting dysbiosis [121]. ...
This review explores the complex relationship between gut dysbiosis and hematological malignancies, focusing on graft-versus-host disease (GvHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. We discuss how alterations in microbial diversity and composition can influence disease development, progression, and treatment outcomes in blood cancers. The mechanisms by which the gut microbiota impacts these conditions are examined, including modulation of immune responses, production of metabolites, and effects on intestinal barrier function. Recent advances in microbiome-based therapies for treating and preventing GvHD are highlighted, with emphasis on full ecosystem standardized donor-derived products. Overall, this review underscores the growing importance of microbiome research in hematology–oncology and its potential to complement existing treatments and improve outcomes for thousands of patients worldwide.
... The introduction of donor microbiota aids in the reestablishment of healthy levels of short-chain fatty acids (SCFAs), such as butyrate, which are essential for gut barrier integrity and immune system modulation. This microbial balance restoration is critical for reducing inflammation and improving gut health (16)(17)(18)(19). ...
... Furthermore, the newly established microbiota can generate bioactive substances that promote gut health and protect against future infections. This continual interaction between the transplanted and indigenous microbiota ensures a long-term therapeutic effect, helping to resolve symptoms and reduce the occurrence of disorders such as recurrent C. difficile infection (16)(17)(18)(19). ...
The human gastrointestinal (GI) tract microbiome is a complex and all-encompassing ecological system of trillions of microorganisms. It plays a vital role in digestion, disease prevention, and overall health. When this delicate balance is disrupted, it can lead to various health issues. Fecal microbiota transplantation (FMT) is an emerging therapeutic intervention used as an adjuvant therapy for many diseases, particularly those with dysbiosis as their underlying cause. Its goal is to restore this balance by transferring fecal material from healthy donors to the recipients. FMT has an impressive reported cure rate between 80% and 90% and has become a favored treatment for many diseases. While FMT may have generally mild to moderate transient adverse effects, rare severe complications underscore the importance of rigorous donor screening and standardized administration. FMT has enormous potential as a practical therapeutic approach; however, additional research is required to further determine its potential for clinical utilization, as well as its safety and efficiency in different patient populations. This comprehensive literature review offers increased confidence in the safety and effectiveness of FMT for several diseases affecting the intestines and other systems, including diabetes, obesity, inflammatory and autoimmune illness, and other conditions.
... 10 FMT is a potential intervention to reshape the gut microbiota and treat metabolic dysfunction and autoimmune disease. 11,12 It involves transferring fecal microbial communities from a healthy donor to restore diversity and function. Initially used mainly for recurrent Clostridiodes difficile infection, FMT has now also been applied to other conditions, including metabolic disorders. ...
The human microbiome, particularly the gut microbiome, has emerged as a central determinant of health and disease. Dysbiosis, an imbalance in the microbial composition of the gut, is associated with a variety of metabolic and other diseases, highlighting the potential for microbiota-targeted treatments. Fecal microbiota transplantation has received considerable attention as a promising therapy to modulate the gut microbiome and restore microbial homeostasis. However, challenges remain, including standardization, safety, and long-term efficacy. This review summarizes current knowledge on fecal microbiota transplantation and describes the next generation therapies targeting microbiome. This review looked at the mechanistic understanding of fecal microbiota transplantation and alternative strategies, elucidating their potential role in improving dysbiosis-associated metabolic disorders, such as obesity, and type 2 diabetes and others. Additionally, this review discussed the growing application of therapies targeting the gut microbiome. Insights from clinical trials, preclinical studies, and emerging technologies provide a comprehensive overview of the evolving landscape of microbiome-based interventions. Through a critical assessment of current advances and prospects, this review aims to highlight the therapeutic potential of targeting gut microbiome and pave the way for innovative approaches in precision medicine and personalized treatments.
... The adult intestinal microbiota varies greatly among individuals and is primarily influenced by factors such as host genetics, diet, and the environment. The intestinal microbiota has a significant impact on the metabolic processes, immune regulation, development, and physiology of the host organism [28]. ...
Acute-on-Chronic Liver Failure (ACLF) is an acute and severe disease involving single or multiple organ failure. Due to the unclear pathogenesis, there is still a lack of effective drug treatment. Intestinal microbiota is closely related to Bile Acid (BA) metabolism. In the progression of chronic liver disease to ACLF, BA metabolism disorder is often accompanied by intestinal microbiota imbalance, which affect one another mutually. This article reviewed the role of BA metabolism and intestinal microbiota in the progression of ACLF, which aims to explore potential new targets for the treatment of ACLF.
... FMT is an emerging potent method for restoring the gut ecosystem. The species-rich microbiomes as well as their products and metabolites from healthy donors can increase the microbial diversity, alter the production of metabolites from certain microbes and the host, and alter the host immune response [181]. Studies in mouse models have shown that transplantation of the faecal microbiome from healthy (wild-type) mice with antibiotic cocktail pretreatment can reverse the abnormalities in the colonic expression of genes related to gut macrophage activity and the circulating inflammatory monocytes, and subsequently reduce brain Aβ burden and phosphorylation of tau protein and improve the cognitive function of AD (ADLP APT ) mice [59,182]. ...
The aetiologies and origins of neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS) and Huntington’s disease (HD), are complex and multifaceted. A growing body of evidence suggests that the gut microbiome plays crucial roles in the development and progression of neurodegenerative diseases. Clinicians have come to realize that therapeutics targeting the gut microbiome have the potential to halt the progression of neurodegenerative diseases. This narrative review examines the alterations in the gut microbiome in AD, PD, ALS and HD, highlighting the close relationship between the gut microbiome and the brain in neurodegenerative diseases. Processes that mediate the gut microbiome–brain communication in neurodegenerative diseases, including the immunological, vagus nerve and circulatory pathways, are evaluated. Furthermore, we summarize potential therapeutics for neurodegenerative diseases that modify the gut microbiome and its metabolites, including diets, probiotics and prebiotics, microbial metabolites, antibacterials and faecal microbiome transplantation. Finally, current challenges and future directions are discussed.
